Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
$132.89
-$1.43(-1.02%)
At close: 4:00 PM EST
$132.89
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$68.70 - $155.53
Previous CloseN/A
Volume388.94K
Average Volume (3M)2.33M
Market Cap
$20.32B
Enterprise Value$21.45B
Total Cash (Recent Filing)$1.63B
Total Debt (Recent Filing)$2.55B
Price to Earnings (P/E)24.3
Beta1.28
Next Earnings
Apr 28, 2026EPS Estimate
1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.35
Shares Outstanding152,900,000
10 Day Avg. Volume2,344,501
30 Day Avg. Volume2,334,828
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.56
Price to Sales (P/S)4.74
P/FCF Ratio22.10
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit7.43
Enterprise Value/Ebitda14.72
Forecast
1Y Price Target
$129.81Price Target Upside-2.32% Downside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)5.13
Revenue Forecast (FY)$4.54B
Bulls Say, Bears Say
Bulls Say
Geographic Recovery And Clinical ConsumablesEasing China import restrictions and broad strength outside China, together with accelerating clinical consumable sales, support revenue resilience and margin improvement.
Multiomics Product LaunchesAnalyst notes that new multiomics products and planned upgrades to the flagship sequencer should boost accuracy, speed and throughput, supporting higher demand for consumables and informatics.
NovaSeq X Transition And PlacementsTransition to the NovaSeq X platform combined with stronger-than-expected instrument placements, including orders from clinical customers, should increase sequencer penetration and consumables pull-through.
Bears Say
Backlog And Demand SoftnessPersistent backlog levels below prior-cycle norms and muted research and applied market demand indicate ordering may stay weak and amplify guidance risk.
Competitor Low-cost SequencersRoche's high-throughput sequencer and multiple rival launches promising much lower per-genome costs and reusable chips pose a material threat to pricing power and market share.
Lengthening Evaluation CyclesIntensifying competition and customer platform reassessments are likely to slow ordering, lengthen evaluation cycles and reduce near-term placements and consumables revenue.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $68.70 and its highest was $155.53 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $20.32B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Apr 28, 2026 which is in 56 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Feb 05, 2026. The company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.242 by $0.108.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.06.
How many shares outstanding does Illumina have?
Illumina has 152,900,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.35 in its last earnings report, beating expectations of $1.242. Following the earnings report the stock price went down -10.396%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$129.81 (-2.32% Downside)
$129.81 (-2.32% Downside)
Blogger Sentiment
Bullish
ILMN Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 251.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $713.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.75%
12-Months-Change
Fundamentals
Return on Equity
33.36%
Trailing 12-Months
Asset Growth
5.41%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
ILMN Company Deck
ILMN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a positive operational rebound: Illumina beat Q4 expectations, returned to ex‑China growth for the year, delivered strong clinical consumables acceleration (+20% ex‑China in Q4), expanded margins and EPS, generated healthy cash flow, advanced multiomics (Somalogic) and data/AI initiatives (BioInsight). Key near‑term headwinds are concentrated in Greater China (export restrictions and revenue decline), a muted academic/research market (expected mid‑high single‑digit declines), tariff impacts on gross margins (~205 bps), and short‑term dilution from the Somalogic acquisition (~$0.18 EPS, ~100 bps margin). Overall the positive commercial momentum, profitability and cash generation outweigh these challenges, though execution and geopolitics are notable risks.View all ILMN earnings summariesILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILMN Stock 12 Month Forecast
Average Price Target
$129.81
▼(-2.32% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---